CAJ | 학술논문

目的：研究芪鹿消白方治疗2~3期慢性肾脏病脾肾亏虚、痰瘀痹络型患者的临床疗效。方法采用随机、对照的方法,将55例门诊患者分成2组,西药组18例、中药组37例。观察时间24周,2组患者均在常规基础治疗基础上,中药组加服芪鹿消白方,西药组加服氯沙坦。在治疗0、8、16、24周时,评价症状积分及证候积分,检测血清肌酐、尿素氮、24 h尿蛋白、肾小球滤过率。结果治疗前2组患者各项指标无明显差异(P>0．05)。治疗后中药组证候积分明显低于西药组(P<0．05)。慢性肾脏病常见症状(如腰酸乏力)在中药组得到明显改善( P<0．05)。中药组治疗后血肌酐、尿素氮及24 h尿蛋白定量、肾小球滤过率均较治疗前有显著改善(P<0.05),而西药组无明显变化( P>0．05)。结论芪鹿消白方对2~3期慢性肾脏病脾肾亏虚、痰瘀痹络型患者在改善症状、降低证候积分值、保护肾功能方面显示了较好的临床疗效。
목적：연구기록소백방치료2~3기만성신장병비신우허、담어비락형환자적림상료효。방법채용수궤、대조적방법,장55례문진환자분성2조,서약조18례、중약조37례。관찰시간24주,2조환자균재상규기출치료기출상,중약조가복기록소백방,서약조가복록사탄。재치료0、8、16、24주시,평개증상적분급증후적분,검측혈청기항、뇨소담、24 h뇨단백、신소구려과솔。결과치료전2조환자각항지표무명현차이(P>0．05)。치료후중약조증후적분명현저우서약조(P<0．05)。만성신장병상견증상(여요산핍력)재중약조득도명현개선( P<0．05)。중약조치료후혈기항、뇨소담급24 h뇨단백정량、신소구려과솔균교치료전유현저개선(P<0.05),이서약조무명현변화( P>0．05)。결론기록소백방대2~3기만성신장병비신우허、담어비락형환자재개선증상、강저증후적분치、보호신공능방면현시료교호적림상료효。
Objective To study the effectiveness and safety of Qilu Xiaobai formula ( QLXB) , a Chinese herbal compound formulated by the TCM principle of invigorating spleen and restoring virility with dred-ging collateral and removing damp, on chronic kidney disease(CKD) patients at stage 2 ~3 with syn-drome of spleen-kidney deficiency and phlegm-stasis obstructing collateral. Methods 55 outpatients were divided randomly into Western medicinal group ( n=18 ) and QLXB group ( n=37 ) . All the pa-tients in two groups were treated basic therapy, besides, those in Western medicinal group took orally losartan while QLXB group took QLXB formula for 24 weeks. At the time point of 0, 8, 16 and 24 week, score of symptoms and score of syndrome were calculated by completing a questionnaire, serum creatinine (Scr), blood urea nitrogen(BUN), urinary protein in 24-hour(24UP) and glomerular filtration rate(eG-FR) were measured. Results There was no statistical difference of each index between two groups be-fore treatment (P>0. 05). After treatment, symptom scores of QLXB group were significantly lower than those in the Western medicinal group (P<0. 05). The score of soreness of loins and fatigue was signifi-cantly decreased in QLXB group than that in Western medicinal group (P<0. 05). The concentration of Scr,Bun,24 UP and eGFR was significantly lower in QLXB group than Western medicinal group ( P<0. 05). Conclusion QLXB was safe and effective for treatment of CKD patients at stage 2~3.